Introduction:
During the last month of the year 2019, certain cases of atypical
pneumonia were reported in Huanan Seafood Wholesale Market, Wuhan, a
district of Hubei province of China1. This idiopathic
pneumonia was declared to be caused by a new strain of the coronavirus
family, previously unknown to humans, by the research teams. The WHO
tentatively named this virus 2019 Novel Corona Virus (nCov-19) in
January 20202. Later, the virus was named SARS COV-2
because of the striking resemblance of the genetic sequence of nCoV-19
with the Severe Acute Respiratory Syndrome
Coronavirus3. This disease has reached almost 213
countries, and territories around the world have reported a total of
12,418,777 cases of COVID-19 that originated from Wuhan, China, and a
death toll of 558,082 to date4. The details on the
pathogenesis of SARS-CoV-2 and its proliferation are uncertain. Hence,
no vaccine or treatment guidelines have yet been made for its prevention
and cure5.
Moreover, therapeutic strategies against SARS-CoV-2 depend on the
effectiveness of various drugs on other strains of coronavirus, i.e.,
SARS-CoV and MERS-CoV. Various strategies based on different mechanisms
of action are being employed to find a successful treatment agent.
Therefore, the review of the COVID- 19 medication is of practical
significance. In this study, COVID-19 treatment therapies are thoroughly
reviewed.